Update on the Burkholderia cepacia complex

Current Opinion in Pulmonary Medicine

Volumn 11, Issue 6, 2005, Pages 528-533

  LiPuma, John J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Burkholderia cepacia complex; Cystic fibrosis; Pulmonary infection

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA MULTIVORANS; CYSTIC FIBROSIS; GENOTYPE; HUMAN; INFECTION CONTROL; LUNG INFECTION; NOMENCLATURE; RESPIRATORY TRACT INFECTION; REVIEW; TAXONOMY;

EID: 27644445124     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000181475.85187.ed     Document Type: Review

References (63)

1. Mahenthiralingam E, Urban TA, Goldberg JB. The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 2005; 3:144-156. This is an excellent and comprehensive review of recent work exploring putative Bcc virulence factors and pathogenic mechanisms in the cystic fibrosis lung.
2. Vandamme P, Holmes B, Vancanneyt M, et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol 1997; 47: 1188-1200.
3. Vermis K, Coenye T, LiPuma JJ, et al. Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. Int J Syst Evol Microbiol 2004; 54:689-691.
4. Storms V, Van Den Vreken N, Coenye T, et al. Polyphasic characterisation of Burkholderia cepacia-like isolates leading to the emended description of Burkholderia pyrrocinia. Syst Appl Microbiol 2004; 27:517-526.
5. Reik R, Spilker T, LiPuma JJ. Distribution of Burkholderia cepacia complex species recovered from persons with or without cystic fibrosis. J Clin Microbiol 2005; 43:2926-2928. This paper reports the distribution of Bcc species among a very large cohort of infected cystic fibrosis patients. It further shows how the distribution of species differs between cystic fibrosis and non - cystic fibrosis populations and how this distribution appears to be changing over time among cystic fibrosis patients.
6. LiPuma JJ, Dasen SE, Nielson DW, et al. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 1990; 336:1094-1096.
7. Carroll K, Romagnoli M, Crost A, et al. Comparison of three commercial systems and an extended phenotypic battery to PCR based analyses for the identification of Burkholderia cepacia complex and related species [abstract]. In: Abstracts of the 105th General Meeting, American Society for Microbiology; 5-9 June 2005; Atlanta, GA.
8. Taylor PC, McLaws M-L, De Borde M, Pritchard R. Isolation and identification of Burkholderia cepacia by participants in an external Quality Assurance Program (QAP) between 1994 and 1999. For Pathol 2004; 36:352-357.
9. Brisse S, Cordevant C, Vandamme P, et al. Species distribution and ribotype diversity of Burkholderia cepacia complex isolates from French patients with cystic fibrosis. J Clin Microbiol 2004; 42:4824-4827.
10. Speert DP, Henry D, Vandamme P, et al. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg Infect Dis 2002; 8:181-187.
11. Agodi A, Barchitta M, Giannino V, et al. Burkholderia cepacia complex in cystic fibrosis and non-cystic fibrosis patients: identification of a cluster of epidemic lineages. J Hosp Infect 2002; 50:188-195.
12. McDowell A, Mahenthiralingam E, Dunbar KEA, et al. Epidemiology of Burkholderia cepacia complex species recovered from cystic fibrosis patients: issues related to patient segregation. J Med Microbiol 2004; 53:663-668. This paper describes an analysis of Bcc recovered from several European cystic fibrosis centers, providing the distribution of species in these centers and again documenting that BCESM and cblA are not reliable markers of apparently transmissible strains.
13. Shehabi AA, Abu-Al-Soud W, Mahafzah A, et al. Investigation of Burkholderia cepacia nosocomial outbreak with high fatality in patients suffering from diseases other than cystic fibrosis. Scand J Infect Dis 2004; 36:174-178.
14. Hutchinson J, Runge W, Mulvey M, et al. Burkholderia cepacia infections associated with intrinsically contaminated ultrasound gel: the role of microbial degradation of parabens. Infect Control Hosp Epidemiol 2004; 25:291-296.
15. Balkhy HH, Cunningham G, Francis C, et al. A National Guard outbreak of Burkholderia cepacia infection and colonization secondary to intrinsic contamination of albuterol nebulization solution. Am J Infect Control 2005; 33: 182-188.
16. Nasser RM, Rahi AC, Haddad MF, et al. Outbreak of Burkholderia cepacia bacteremia traced to contaminated hospital water used for dilution of an alcohol skin antiseptic. Infect Control Hosp Epidemiol 2004; 25:231-239.
17. Souza AV, Moreira CR, Pasternak J, et al. Characterizing uncommon Burkholderia cepacia complex isolates from an outbreak in a haemodialysis unit. J Med Microbiol 2004; 53:999-1005.
18. Moreira BM, Leobons MB, Pellegrino FL, et al. Ralstonia pickettii and Burkholderia cepacia complex bloodstream infections related to infusion of contaminated water for injection. J Hosp Infect 2005; 60:51-55.
19. Doit C, Loukil C, Simon AM, et al. Outbreak of Burkholderia cepacia bacteremia in a pediatric hospital due to contamination of lipid emulsion stoppers. J Clin Microbiol 2004; 42:2227-2230.
20. CDC. Manufacturer's recall of nasal spray contaminated with Burkholderia cepacia complex. Morb Mortal Wkly Rep 2004; 53:246.
21. Chen JS, Witzmann KA, Spilker T, et al. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr 2001; 139: 643-649.
22. Coenye T, LiPuma JJ. Population structure analysis of Burkholderia cepacia genomovar III: varying degrees of genetic recombination characterize major clonal complexes. Microbiology 2003; 149:77-88.
23. LiPuma JJ, Spilker T, Coenye T, Gonzalez CF. An epidemic Burkholderia cepacia complex strain identified in soil. Lancet 2002; 359:2002-2003.
24. Coenye T, Spilker T, Van Schoor A, et al. Recovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe. Thorax 2004; 59: 952-954.
25. Biddick R, Spilker T, Martin A, LiPuma JJ. Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol Lett 2003; 228:57-62.
26. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003; 31(Suppl): S1-62.
27. Manno G, Dalmastri C, Tabacchioni S, et al. Epidemiology and clinical course of Burkholderia cepacia complex infections, particularly those caused by different Burkholderia cenocepacia strains, among patients attending an Italian cystic fibrosis center. J Clin Microbiol 2004; 42:1491-1497.
28. Ledson MJ, Gallagher MJ, Corkill JE, et al. Cross infection between cystic fibrosis patients colonized with Burkholderia cepacia. Thorax 1998; 53:432-436.
29. Bernhardt SA, Spilker T, Coffey T, LiPuma JJ. Burkholderia cepacia complex in cystic fibrosis: frequency of strain replacement during chronic infection. Clin Infect Dis 2003; 37:780-785.
30. Seo ST, Tsuchiya K. PCR-based identification and characterization of Burkholderia cepacia complex bacteria from clinical and environmental sources. Lett Appl Microbiol 2004; 39:413-419.
31. Remette A, LiPuma JJ, Tiedje JM. Species abundance and diversity of Burkholderia cepacia complex in the environment. Appl Environ Microbiol 2005; 71:1193-1201.
32. Dalmastri C, Pirone L, Tabacchioni S, et al. Efficacy of species-specific recA PCR tests in the identification of Burkholderia cepacia complex environmental isolates. FEMS Microbiol Lett 2005; 246:39-45.
33. Vermis K, Brachkova M, Vandamme P, Nelis H. Isolation of Burkholderia cepacia complex genomovars from waters. Syst Appl Microbiol 2003; 26: 595-600.
34. Burns JL, Gibson RL, McNamara S, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001; 183:444-452.
35. Renders N, Verbrugh H, Van Belkum A. Dynamics of bacterial colonisation in the respiratory tract of patients with cystic fibrosis. Infect Genet Evol 2001; 1: 29-39.
36. Mahenthiralingam E, Vandamme P, Campbell ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001; 33:1469-1475.
37. Jones AM, Dodd ME, Govan JR, et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004; 59:948-951. This paper describes poor clinical outcome in cystic fibrosis patients infected by the B. cenocepacia ET12 strain.
38. De Boeck K, Malfroot A, Van Schil L, et al. Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients. Eur Respir J 2004; 23:851-856.
39. th Meeting of the International Burkholderia cepacia Working Group; 5-7 April 2002; San Antonio, TX. http://go.to/cepacia
40. LiPuma JJ, Marks-Austin KA, Holsclaw DS Jr, et al. Inapparent transmission of Pseudomonas (Burkholderia) cepacia among patients with cystic fibrosis. Pediatr Infect Dis J 1994; 13:716-719.
41. Ledson MJ, Gallagher MJ, Jackson M, et al. Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax 2002; 57:142-145.
42. De Soyza A, Morris K, McDowell A, et al. Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation. Thorax 2004; 59:526-528.
43. Courtney JM, Dunbar KE, McDowell A, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 2004; 3: 93-98.
44. Blackburn L, Brownlee K, Conway S, Denton M. 'Cepacia syndrome' with Burkholderia multivorans, 9 years after initial colonization. J Cyst Fibros 2004; 3:133-134.
45. Fauroux B, Hart N, Belfar S, et al. Burkholderia cepacia is associated with pulmonary hypertension and increased mortality among cystic fibrosis patients. J Clin Microbiol 2004; 42:5537-5541.
46. Otag F, Ersoz G, Salcioglu M, et al. Nosocomial bloodstream infections with Burkholderia stabilis. J Hosp Infect 2005; 59:46-52.
47. Woods CW, Bressler AM, LiPuma JJ, et al. Virulence associated with outbreak-related strains of Burkholderia cepacia complex among a cohort of patients with bacteremia. Clin Infect Dis 2004; 38:1243-1250.
48. Chambers CE, Visser MB, Schwab U, Sokol PA. Identification of N-acylhomoserine lactones in mucopurulent respiratory secretions from cystic fibrosis patients. FEMS Microbiol Lett 2005; 244:297-304.
49. Venturi V, Friscina A, Bertani I, et al. Quorum sensing in the Burkholderia cepacia complex. Res Microbiol 2004; 155:238-244.
50. Eberl L, Tummler B. Pseudomonas aeruginosa and Burkholderia cepacia in cystic fibrosis: genome evolution, interactions and adaptation. Int J Med Microbiol 2004; 294:123-131.
51. Al-Bakri AG, Gilbert P, Allison DG. Immigration and emigration of Burkholderia cepacia and Pseudomonas aeruginosa between and within mixed biofilm communities. J Appl Microbiol 2004; 96:455-463.
52. Tomlin KL, Clark SR, Ceri H. Green and red fluorescent protein vectors for use in biofilm studies of the intrinsically resistant Burkholderia cepacia complex. J Microbiol Methods 2004; 57:95-106.
53. Chiarini L, Cescutti P, Drigo L, et al. Exopolysaccharides produced by Burkholderia cenocepacia recA lineages IIIA and IIIB. J Cyst Fibros 2004; 3:165-172.
54. Conway BA, Chu KK, Bylund J, et al. Production of exopolysaccharide by Burkholderia cenocepacia results in altered cell-surface interactions and altered bacterial clearance in mice. J Infect Dis 2004; 190:957-966.
55. Strino F, Nahmany A, Rosen J, et al. Conformation of the exopolysaccharide of Burkholderia cepacia predicted with molecular mechanics (MM3) using genetic algorithm search. Carbohydr Res 2005; 340:1019-1024.
56. Cunha MV, Sousa SA, Leitao JH, et al. Studies on the involvement of the exopolysaccharide produced by cystic fibrosis-associated isolates of the Burkholderia cepacia complex in biofilm formation and in persistence of respiratory infections. J Clin Microbiol 2004; 42:3052-3058.
57. Sampaio Nogueira CE, Ruggiero JR, Sist P, et al. Conformational features of cepacian: the exopolysaccharide produced by clinical strains of Burkholderia cepacia. Carbohydr Res 2005; 340:1025-1037.
58. De Soyza A, Ellis CD, Khan CMA, et al. Burkholderia cenocepacia lipopolysaccharide, lipid A, and proinflammatory activity. Am J Respir Crit Care Med 2004; 170:70-77.
59. Ortega X, Hunt TA, Loutet S, et al. Reconstitution of O-specific lipopolysaccharide expression in Burkholderia cenocepacia strain J2315, which is associated with transmissible infections in patients with cystic fibrosis. J Bacteriol 2005; 187:1324-1333.
60. Vinion-Dubiel AD, Spilker T, Dean CR, et al. Correlation of wbil genotype, serotype, and isolate source within species of the Burkholderia cepacia complex. J Clin Microbiol 2004; 42:4121-4126.
61. Nair BM, Cheung KJ Jr, Griffith A, Burns JL. Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia). J Clin Invest 2004; 113:464-473.
62. Nair BM, Joachimiak LA, Chattopadhyay S, et al. Conservation of a novel protein associated with an antibiotic efflux operon in Burkholderia cenocepacia. FEMS Microbiol Lett 2005; 245:337-344.
63. Aaron SD, Ferris W, Henry DA, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000; 161:1206-1212.